Table 4.

Associations between long‐term exposure to antipsychotics with prolactin‐inducing properties (equivalent to ≥10 000 mg of olanzapine) and risk of breast cancer, specified by patient subgroups or cancer subtype or stage

Subgroup	Cases Exposed/unexposed	Controls Exposed/unexposed	Adjusted ORa	Adjusted ORb
Age
<50 years	66/9845	648/97 906	1.02 (0.79–1.31)	1.02 (0.68–1.54)
50–69 years	441/31 424	3474/316 605	1.28 (1.16–1.42)	1.20 (1.04–1.38)
70+ years	186/14 140	1537/141 446	1.21 (1.03–1.41)	1.16 (0.96–1.41)
Subtype
Ductal adenocarcinoma	496/41 958	4259/421 053	1.17 (1.07–1.29)	1.14 (1.01–1.30)
Lobular adenocarcinoma	80/6984	728/69 373	1.09 (0.86–1.38)	1.03 (0.75–1.43)
Adenocarcinoma NOS	40/3342	324/33 402	1.23 (0.89–1.72)	1.20 (0.77–1.87)
Carcinoma NOS	74/2906	329/29 914	2.32 (1.79–3.00)	1.90 (1.31–2.76)
Estrogen receptor status
Positive	483/34 712	3699/348 626	1.31 (1.19–1.45)	1.29 (1.13–1.47)
Negative	64/7540	742/75 453	0.87 (0.67–1.12)	0.92 (0.65–1.29)
Unknown	146/13 157	1218/131 878	1.20 (1.01–1.43)	1.01 (0.80–1.28)
Stage
Localized	270/22 464	2471/224 821	1.09 (0.96–1.24)	1.01 (0.85–1.20)
Nonlocalized	263/18 798	2077/188 181	1.28 (1.13–1.46)	1.37 (1.15–1.65)
Unknown	160/14 147	1111/142 955	1.45 (1.23–1.72)	1.24 (0.99–1.55)

OR = odds ratio; NOS = tot otherwise specified

^aAdjusted for age and calendar‐time (by design).

^bFully adjusted model, see section ‘Analytical variables’.